High levels of CD8+ tumour-infiltrating lymphocytes (TILs) have been shown to predict better outcomes in various cancers such as melanoma [58], ovarian [59], colorectal [60], breast [61] and head and neck [62]. This evidence concerns the gene CD8A and cancer.